Sedatives

Myconic Capital Corp. Signs Letter of Intent for Acquisition of NY Ketamine Medical Practice, PLLC

Retrieved on: 
Monday, April 5, 2021

In otherwise treatment resistant depression patients, numerous studies have shown that intravenous ketamine therapy has an overall success rate of 70%.

Key Points: 
  • In otherwise treatment resistant depression patients, numerous studies have shown that intravenous ketamine therapy has an overall success rate of 70%.
  • Based on the success of its New York City clinic, NY Ketamine Infusions has opened an additional clinic in Long Island, NY (Melville).
  • Dr. Brooks also continues to act as a consultant for privately owned practices in Albany, NY and Madrid, Spain.
  • Myconic Capital Corp is an investment issuer with a diversified portfolio that is focused on emerging companies active in the high-tech, real estate, cannabis, mining and health & wellness sectors.

Urbana Corporation Announces Investment in Integrated Grain Processors Co-operative Inc. to Expand its Innovative Technologies Portfolio

Retrieved on: 
Monday, March 29, 2021

"We are very excited about Urbana's investment in IGPC and the possibilities for its recent plant expansion as travel becomes realistic again."

Key Points: 
  • "We are very excited about Urbana's investment in IGPC and the possibilities for its recent plant expansion as travel becomes realistic again."
  • ABOUT INTEGRATED GRAIN PROCESSORS CO-OPERATIVE INC.
    IGPC distills ethanol to blend with gasoline, reducing carbon emissions from fossil fuels.
  • https://www.igpc.ca
    Urbana Corporation is a diversified corporation with a focus on financial services, information services and innovative technologies.
  • The portfolio mix of actively managed publicly traded securities with private equity investments has generated significant long-term investment results.

PharmaTher Advancing Research for Novel Microneedle Delivery of Ketamine

Retrieved on: 
Wednesday, March 24, 2021

The research will be led by Professor Ryan Donnelly, a world leader in the research of microneedle delivery technologies.

Key Points: 
  • The research will be led by Professor Ryan Donnelly, a world leader in the research of microneedle delivery technologies.
  • Most recently, Professor Donnelly's lab successfully completed research and published a paper titled Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery.
  • His research validates the delivery of esketamine, theS(+)enantiomerof ketamine, in a novel microneedle patch which may overcome the drawbacks associated with ketamine administration in an intravenous or nasal spray format.1
    The proposed ketamine and KETABET MN patch offer a potential game-changing therapeutic solution for various unmet medical needs.
  • Despite its potential, ketamine has the potential for abuse and misuseleading to problems such as dissociative, hallucinogenic and amnesic effects6.

Dr. Ditzell Psychiatry, PLLC Opens New York Psychiatry Ketamine Treatment Center for Around-the-clock In-person Visits

Retrieved on: 
Thursday, March 18, 2021

Ketamine has been commonly used as a safe anesthetic in hospitals and medical settings for over a decade.

Key Points: 
  • Ketamine has been commonly used as a safe anesthetic in hospitals and medical settings for over a decade.
  • Ketamine Infusion Therapy is an IV procedure administered while undergoing a psychotherapy session with Dr. Ditzell himself.
  • The newly remodeled treatment center is located at 65 Broadway #901, New York City, NY.
  • Host of Psychs & The City Podcast, Dr. Ditzell has been featured in Forbes, Healthline, and is a medical reviewer for Insider.

REX American Resources to Report Fiscal 2020 Q4 Results and Host Conference Call and Webcast on Thursday, March 25

Retrieved on: 
Thursday, March 18, 2021

REX American Resources Corporation (NYSE: REX), a leading ethanol company, announced today that it will report its fiscal 2020 fourth quarter financial results on Thursday, March 25, pre-market and will host a conference call and webcast at 11:00 a.m.

Key Points: 
  • REX American Resources Corporation (NYSE: REX), a leading ethanol company, announced today that it will report its fiscal 2020 fourth quarter financial results on Thursday, March 25, pre-market and will host a conference call and webcast at 11:00 a.m.
  • To access the conference call, interested parties may dial 212/231-2920 (domestic and international callers).
  • Participants can also listen to a live webcast of the call on the REX website at www.rexamerican.com/Corp/Page4.aspx .
  • REX American Resources has interests in six ethanol production facilities, which in aggregate shipped approximately 605 million gallons of ethanol over the twelve-month period ended October 31, 2020.

American Society of Ketamine Physicians, Psychotherapists and Practitioners Recommends the Ethical Prescription and Administration of Ketamine

Retrieved on: 
Friday, March 12, 2021

One such example includes the unethical prescription and administration of IV ketamine in a home or even hotel room without an in-person evaluation by the prescribing provider.

Key Points: 
  • One such example includes the unethical prescription and administration of IV ketamine in a home or even hotel room without an in-person evaluation by the prescribing provider.
  • Their purpose is to serve as guidelines for safe and ethical administration of ketamine in practice.
  • (American Society of Ketamine Physicians, Psychotherapists, and Practitioners) In addition, ASKP3 composed a comprehensive Ethics Statement for ketamine providers in 2020 that is currently pending publication.
  • ASKP3: American Society of Ketamine Physicians, Psychotherapists, and Practitioners, 2020, ASKP3 Standards - ASKP.

Champignon Brands Restates Financial Statements and MD&A Files Listing Statement

Retrieved on: 
Friday, March 12, 2021

Complete details on the effect of the restatements are included in the notes to the Restated Financial Statements and in the MD&A.

Key Points: 
  • Complete details on the effect of the restatements are included in the notes to the Restated Financial Statements and in the MD&A.
  • The Restated Financial Statements and MD&A supersede the previously filed financial statements and MD&A.
  • The Interim Financial Statements and MD&A reflect the acquisition of AltMed Capital Corp. ("AltMed") on April 30, 2020 (the "Transaction").
  • Champignon Brands Inc. ( https://champignonbrands.com ) is a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions.

Shareholder Alert: Robbins LLP Announces that Vanda Pharmaceuticals Inc. (VNDA) Class Action Survives Motion to Dismiss

Retrieved on: 
Thursday, March 11, 2021

Shareholder rights law firm Robbins LLP announces that Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) may face damages caused by a pending securities lawsuit.

Key Points: 
  • Shareholder rights law firm Robbins LLP announces that Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) may face damages caused by a pending securities lawsuit.
  • Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system disorders.
  • Specifically, Vanda schemed to promote its drugs Fanapt and Hetlioz for "off-label" uses in addition to other prohibited promotional strategies.
  • On March 10, 2021, U.S. District Judge Frederic Block denied Vanda and its CEO's motion to dismiss the securities class action against, paving the way for litigation to proceed.

Myconic Capital Corp. Signs Letter of Intent for Acquisition of Mindscape Ketamine & Infusions Therapy, PLLC

Retrieved on: 
Wednesday, March 10, 2021

After ketamine-based treatments helped to alleviate depression-related symptoms experienced by his wife, Dr. Henderson was inspired to open Mindscape to avail such treatments to the general public.

Key Points: 
  • After ketamine-based treatments helped to alleviate depression-related symptoms experienced by his wife, Dr. Henderson was inspired to open Mindscape to avail such treatments to the general public.
  • The Houston-based clinic, which administers ketamine through intravenous therapy (IV), is characterized by its spa-like atmosphere designed to put patients at ease.
  • Ketamine was first synthesized in 1962, and was successfully patented as a human anaesthetic in the United States in 1966.
  • We look forward to exploring the potential directions in which we can take Mindscape as ketamine treatments continue to gain acceptance and popularity across the United States.

FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia

Retrieved on: 
Wednesday, March 10, 2021

The incidence of somnolence was low and did not increase with daridorexant 50 mg compared to placebo.

Key Points: 
  • The incidence of somnolence was low and did not increase with daridorexant 50 mg compared to placebo.
  • Patients reported no next-morning sleepiness compared to placebo as assessed by the morning visual analogue scale (VAS).
  • In April and July of 2020, Idorsia reported positive results in each of the two pivotal Phase 3 studies of daridorexant in patients with insomnia.
  • Daridorexant is a dual orexin receptor antagonist (DORA) designed and developed for the treatment of insomnia.